Loading stock data…
MRK.DE
€112.90+0.05 (+0.04%)
Market ClosedLast close May 11
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Merck KGaA in the Healthcare sector is trading at €112.90. The stock is currently 14% below its 52-week high of €131.65, remaining 0.3% below its 200-day moving average. Technical signals show neutral RSI of 45 and bullish MACD crossover, explaining why MRK.DE maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price€112.90
Potential Upside
2.7%
Whystock Fair Value€115.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target€141.27+25.1%
Range€112.00 – €179.00
Fundamentals
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€50.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.27
Beta
Defensive asset. Lower volatility than the S&P 500.
0.80
Div Yield
Strong income play. Yield provides a meaningful total return floor.
187.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.92%
Volume
Today's trading volume
316,490
Recent News
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +13.66% and +35.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Merck KGaA (XTRA:MRK) Investment Story Is Shifting As Analysts Reset Expectations
Merck KGaA’s fair value price target has been reset to €141.27 from €143.20, a modest reduction of about 1.4% that keeps the stock in a similar valuation zone. This adjustment aligns with a wave of recent analyst actions, where several firms have trimmed targets to around €125 to €135, while one major house has started coverage with a neutral stance. As you read on, you will see how these mixed signals fit together and how to track the evolving story around Merck KGaA from here. Analyst Price...
Merck KGaA AGM: CEO Garijo’s final address, stable €2.20 dividend, Beckmann to take over May 1
Merck KGaA (ETR:MRK) opened its 2026 Annual General Meeting (AGM) in person at Frankfurt’s Jahrhunderthalle, marking the company’s first in-person AGM at the venue since 2019, according to Supervisory Board Chairman Michael Kleinemeier, who chaired the meeting. Kleinemeier formally confirmed the me
Merck KGaA and Remepy join forces to develop combo drug-digital therapies
The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.